These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1120398)

  • 1. Elimination of procainamide in end stage renal failure.
    Gibson TP; Lowenthal DT; Nelson HA; Briggs WA
    Clin Pharmacol Ther; 1975 Mar; 17(3):321-9. PubMed ID: 1120398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Acetylprocainamide levels in patients with end-stage renal failure.
    Gibson TP; Matusik EJ; Briggs WA
    Clin Pharmacol Ther; 1976 Feb; 19(2):206-12. PubMed ID: 1261157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function.
    Drayer DE; Lowenthal DT; Woosley RL; Nies AS; Schwartz A; Reidenberg MM
    Clin Pharmacol Ther; 1977 Jul; 22(1):63-9. PubMed ID: 872496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of procainamide and N-acetylprocainamide in renal failure.
    Gibson TP; Atkinson AJ; Matusik E; Nelson LD; Briggs WA
    Kidney Int; 1977 Dec; 12(6):422-9. PubMed ID: 609192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Raehl CL; Moorthy AV; Beirne GJ
    Nephron; 1986; 44(3):191-4. PubMed ID: 2431330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
    Kroboth PD; Mitchum K; Puschett JB
    Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations.
    Atkinson AJ; Krumlovsky FA; Huang CM; del Greco F
    Clin Pharmacol Ther; 1976 Nov; 20(5):585-92. PubMed ID: 975731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis.
    Stec GP; Atkinson AJ; Nevin MJ; Thenot JP; Ruo TI; Gibson TP; Ivanovich P; del Greco F
    Clin Pharmacol Ther; 1979 Nov; 26(5):618-28. PubMed ID: 91468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thin-layer chromatographic determination of procainamide and N-acetylprocainamide in human serum and urine at single-dose levels.
    Kark B; Sistovaris N; Keller A
    J Chromatogr; 1983 Oct; 277():261-72. PubMed ID: 6196373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of procainamide and N-acetylprocainamide in rats.
    Kamath BL; Lai CM; Gupta SD; Durrani MJ; Yacobi A
    J Pharm Sci; 1981 Mar; 70(3):299-302. PubMed ID: 6167709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of the EMIT procainamide and N-acetylprocainamide assay.
    Walberg CB; Wan SH
    Ther Drug Monit; 1979; 1(1):47-56. PubMed ID: 95422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis.
    Sica DA; Yonce C; Small R; Cefali E; Harford A; Poynor W
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):59-64. PubMed ID: 2457560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme immunoassay, liquid chromatography, and spectrofluorometry compared for the determination of procainamide and N-acetylprocainamide in serum.
    Pape BE
    J Anal Toxicol; 1982; 6(1):44-8. PubMed ID: 6176781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration.
    Domoto DT; Brown WW; Bruggensmith P
    Ann Intern Med; 1987 Apr; 106(4):550-2. PubMed ID: 2435200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amiodarone on the disposition of procainamide in the rat.
    Liu LL; Knowlton PW; Svensson CK
    J Pharm Sci; 1988 Aug; 77(8):662-5. PubMed ID: 3210153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of procainamide in patients with chronic heart failure, chronic respiratory failure and chronic renal failure.
    du Souich P; Erill S
    Eur J Clin Pharmacol; 1978 Nov; 14(1):21-7. PubMed ID: 729603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoperfusion for treatment of N-acetylprocainamide intoxication.
    Braden GL; Fitzgibbons JP; Germain MJ; Ledewitz HM
    Ann Intern Med; 1986 Jul; 105(1):64-5. PubMed ID: 2424355
    [No Abstract]   [Full Text] [Related]  

  • 20. Procainamide pharmacokinetics in beagles: urinary pH dependency and comparison with n-acetylprocainamide.
    Baer DT; Barkus JC
    Res Commun Chem Pathol Pharmacol; 1977 Jun; 17(2):333-6. PubMed ID: 17895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.